All rights reserved. Clinical trial information: NCT04221542.doi:10.1200/JCO.2021.39.6_suppl.TPS183William Kevin KellyDavid William PookLeonard Joseph ApplemanDavid Michael WaterhouseTanya B. DorffJournal of Clinical Oncology
AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment.Significance:Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and ...
来源期刊 Journal of Clinical Oncology 2021/02/20 研究点推荐 AMG 509 metastatic castration-resistant prostate cancer XmAb 2+1 immune therapy 站内活动 0关于我们 百度学术集成海量学术资源,融合人工智能、深度学习、大数据分析等技术,为科研工作者提供全面快捷的学术服务。在这里我们保持学习的态度,不忘初心...